Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis

This study has been completed.
Information provided by:
Capnia, Inc. Identifier:
First received: March 13, 2008
Last updated: August 17, 2010
Last verified: August 2010
The purpose of this study is to evaluate the effect of nasal CO2 on nasal congestion and other symptoms related to Perennial Allergic Rhinitis.

Condition Intervention Phase
Perennial Allergic Rhinitis
Drug: Nasal Carbon Dioxide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion Via Acoustic Rhinometry in Subjects With Perennial Allergic Rhinitis

Resource links provided by NLM:

Further study details as provided by Capnia, Inc.:

Primary Outcome Measures:
  • Determine the dose-related effects of CO2 on nasal congestion assessed by acoustic rhinometry. [ Time Frame: Baseline, Post Treatment: 15 mins, 30 mins, 45 mins, 1 hour, 2 hours, 3 hours, 4 hours ]

Secondary Outcome Measures:
  • Change from baseline in olfactory test scores post-treatment [ Time Frame: Baseline, Post Treatment: 1 hour & 3 hours ]
  • TNSS, TNNSS, and TSS comparisons at multiple timepoints [ Time Frame: Baseline, Post Treatment: 15 mins, 30 mins, 45 mins, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 24 hours ]

Enrollment: 20
Study Start Date: February 2008
Estimated Study Completion Date: July 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
Drug: Nasal Carbon Dioxide
Nasal Carbon Dioxide
Experimental: 2
The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
Drug: Nasal Carbon Dioxide
Nasal Carbon Dioxide
Experimental: 3
The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
Drug: Nasal Carbon Dioxide
Nasal Carbon Dioxide
Experimental: 4
The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
Drug: Nasal Carbon Dioxide
Nasal Carbon Dioxide

Detailed Description:
A randomized study to evaluated the safety and effect of nasal carbon dioxide on nasal congestion using acoustic rhinometry in subjects with perennial allergic rhinitis. The acoustic rhinometry is an instrument that will be used to assess the levels of the nasal congestion in each subject. Approximately 20 men and women ages 19-65 years old who have a history consistent with perennial allergic rhinitis requiring pharmacology for at least 2 years and meet all other eligibility criteria will be enrolled in this study. There will be six (6) visits to the clinic. There will be a screening visit, four (4) treatment visits, and an end of study visit. A subject's participation in the study may last up to 58 days. There will be four different doses given in this study. Each subject will receive 3 different doses of the study drug and one dose of the placebo.

Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a history consistent with minimal 2 year history of perennial allergic rhinitis requiring pharmacotherapy.
  • Positive skin test to perennial allergens (e.g. cats, dogs, house dust mite, etc.)
  • Females of childbearing potential must commit to using an acceptable method of birth control and have a negative pregnancy test

Exclusion Criteria:

  • History of asthma (other than mild or intermittent)
  • Clinically significant nasal disorders
  • Acute or significant sinusitis or upper respiratory infection within 14 days of randomization
  • Have an existing serious medical condition (such as severe emphysema, other respiratory diseases, heart disease, etc.) that precludes participation in the study
  • Use of certain medication s prior to randomization and during study participation
  • Participation in prior study with Nasal CO2
  • Participation in another clinical study within 30 days of planned randomization date and for the duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00638755

United States, Nebraska
Capnia Investigative Site
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Capnia, Inc.
Principal Investigator: Capnia Clinical Study Investigator Capnia Investigative Site
  More Information

Responsible Party: Kristen Yen- Associate Director, Clinical, Capnia, Inc. Identifier: NCT00638755     History of Changes
Other Study ID Numbers: C213
Study First Received: March 13, 2008
Last Updated: August 17, 2010

Keywords provided by Capnia, Inc.:
Allergic Rhinitis
Perennial Allergic Rhinitis
Allergies to perennial allergens
Allergies to perennial allergens (e.g. dog, cat, dust mites, etc.)

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on May 25, 2017